BiotechTube

edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Thromboembolism

Conditions

Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis

Trial Timeline

Oct 1, 2009 → Apr 1, 2013

NCT ID
NCT00986154

About edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin

edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin is a phase 3 stage product being developed by Daiichi Sankyo for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00986154. Target conditions include Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE).

What happened to similar drugs?

6 of 20 similar drugs in Venous Thromboembolism were approved

Approved (6) Terminated (3) Active (12)
✅Dalteparin (Fragmin) + Unfractionated heparinPfizerApproved
✅Apixaban + Standard of CarePfizerApproved
✅ApixabanBristol Myers SquibbApproved
✅enoxaparin sodiumSanofiApproved
✅enoxaparinSanofiApproved
✅Long DOAC + Short DOACBayerApproved
🔄Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00986154Phase 3Completed

Competing Products

20 competing products in Venous Thromboembolism

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
35
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Standard of CareDaiichi SankyoPhase 3
40
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
35
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
40
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
40
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2/3
38
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
26
dalteparin injectionEisaiPhase 3
32
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
29
Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K AntagonistJohnson & JohnsonPhase 2
35